Vineet Laboratories Ltd
Tue 5/05/2026,14:12:54 | NSE : VINEETLAB
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 37.50
Previous Close
₹ 36.74
Volume
46416
Mkt Cap ( Rs. Cr)
₹69.14
High
₹ 37.50
Low
₹ 35.50
52 Week High
₹ 43.50
52 Week Low
₹ 27.96
Book Value Per Share
₹ 13.05
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Vineet Laboratories Ltd
Your Vote -
Buy
33.33%
Hold
0.00%
Sell
66.67%
33.33%
3 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
38.55
4999
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
4999
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Vineet Laboratories Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Vineet Laboratories - Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
-
Vineet Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Vineet Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Vineet Laboratories - Structural Digital Database
-
Vineet Laboratories - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Vineet Laboratories - Trading Window
-
Vineet Laboratories - Copy of Newspaper Publication
-
Vineet Laboratories - Outcome of Board Meeting
-
Vineet Laboratories - Outcome of Board Meeting
-
Vineet Laboratories posts Q3 net profit of Rs 0.85 cr
-
Vineet Laboratories - Unaudited Standalone Financial Results Along With The Limited Review Report For The Period Ended On Dec
-
Vineet Laboratories - Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, February 14, 2026 As Required Unde
-
Vineet Laboratories - Board Meeting Intimation for Considering And Approving The Unaudited Standalone Financial Results Of Th
-
Vineet Laboratories - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Vineet Laboratories - Shareholders meeting
-
Vineet Laboratories - Shareholders meeting
-
Vineet Laboratories - Shareholder Meeting / Postal Ballot-Outcome of EGM
Key fundamentals
Evaluate the intrinsic value of Vineet Laboratories Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 54.6947 | 79.0239 | 64.7723 | 59.7318 | 39.0878 |
| Liabilities | 54.6947 | 79.0239 | 64.7723 | 59.7318 | 39.0878 |
| Equity | 9.219 | 9.219 | 9.219 | 9.219 | 9.219 |
| Gross Profit | -16.2831 | 7.2002 | 7.6597 | 13.2445 | 8.1456 |
| Net Profit | -20.191 | 1.0271 | 1.2525 | 6.6386 | 1.7802 |
| Cash From Operating Activities | 11.4909 | -11.4272 | -9.6162 | 0 | -8.7123 |
| NPM(%) | -26.92 | 0.68 | 0.58 | 3.47 | 0.73 |
| Revenue | 74.995 | 150.5913 | 212.2933 | 191.1723 | 243.4789 |
| Expenses | 91.2781 | 143.3911 | 204.6336 | 177.9278 | 235.3333 |
| ROE(%) | -80.57 | 4.09 | 4.99 | 26.49 | 7.1 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 19 Sep 2022 | 1 | 10 | 0 | 58.75 |
Peers
Other companies within the same industry or sector that are comparable to Vineet Laboratories Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 752.15 | 2.79 | 44.66 | 21.24 | 301.39 | 0.66 |
| Lotus Eye Hospital and Institute Ltd | 115.91 | -0.44 | 373.90 | 77.40 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.70 | 3.63 | 0.00 | 485.58 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 686.30 | -3.69 | 0.00 | 72.99 | -363.15 | 0.00 |
Company Info
Vineet Laboratories Limited ("Resulting Company") is a public limited company incorporated under the provisions of the Companies Act, 2013, on 10th day of November, 2016. The Corporate Identity Number of Resulting Company is U24304TG2016PLC112888. The objects of the Resulting Company enable it to carry on the business of manufacturing of bulk drugs intermediates and API Intermediates. The PAN of the Company is AAFCV6694P. Vineet Laboratories Limited is also been certified as an ISO 14001: 2015 Company by the internationally recognised Quality Management Certification Body, in pursuance of its focus towards Environmental Management System.
Vineet Laboratories Limited ("Resulting Company") is a public limited company incorporated under the provisions of the Companies Act, 2013, on 10th day of November, 2016. The Corporate Identity Number of Resulting Company is U24304TG2016PLC112888. The objects of the Resulting Company enable it to carry on the business of manufacturing of bulk drugs intermediates and API Intermediates. The PAN of the Company is AAFCV6694P. Vineet Laboratories Limited is also been certified as an ISO 14001: 2015 Company by the internationally recognised Quality Management Certification Body, in pursuance of its focus towards Environmental Management System.
Read More
Parent Organisation
Vineet Laboratories Ltd.
Founded
10/11/2016
Managing Director
Mr.Gaddam Venkata Ramana
NSE Symbol
VINEETLABBE
FAQ
The current price of Vineet Laboratories Ltd is ₹ 36.00.
The 52-week high for Vineet Laboratories Ltd is ₹ 37.50 and the 52-week low is ₹ 35.50.
The market capitalization of Vineet Laboratories Ltd is currently ₹ 69.14. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Vineet Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Vineet Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Vineet Laboratories Ltd shares.
The CEO of Vineet Laboratories Ltd is Mr.Gaddam Venkata Ramana, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
